CD79B and lymphoma: Thus, adding venetoclax to RCHOP-like regimens or to the MMAE-conjugated anti-CD79b antibody polatuzumab [62,63] may be strategies to overcome the chemo-resistance associated in a subset of patients with BCL2+ high-grade lymphomas.